[Short-term treatment with leuprolide acetate depot before surgical intervention for uterine leiomyomatosis].
It has been amply demonstrated that uterine leiomyoma possess estrogen receptors. On the basis of this presupposition, it is considered logical to use GnRH-agonists which, by reducing the level of estrogen, also reduce the volume of the leiomyoma, although to a varying extent. The maximum reduction which can be obtained occurs, according to published data, between 3 and 6 months of treatment, attaining mean values of approximately 50%. In the author's experience the treatment period was shortened even further by administering only 2 vials of leuprolide depot each month to women who subsequently underwent hysterectomy. The sample group comprised 30 women with uterine leiomyomatosis, of whom 15 were treated with a GnRH analogue and 15 with placebo. The reduction of uterine volume was evaluated by echography and was found to be 40% in the treated group, whereas non change was detected in the "placebo-group".
D'Anna
R
R
Cattedra di Patologia Ostetrica e Ginecologica, Università degli Studi di Messina.
Palmara
V
V
Lo Re
C
C
Scilipoti
A
A
Leonardi
I
I
D000328:Adult; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007044:Hysterectomy; D018231:Leiomyomatosis / Q000188:drug therapy* / Q000601:surgery; D016729:Leuprolide / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D011292:Premedication; D013997:Time Factors; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
D003692:Delayed-Action Preparations; D016729:Leuprolide
Breve trattamento con leuprolide acetato depot prima di intervento chirurgico per leiomiomatosi uterina.